DGAP-News
Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel
Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with
additional features)
23.07.2015 / 20:04
---------------------------------------------------------------------
PRESS RELEASE N 11 / 2015 of 07/23/2015
Dr. med. Mariola Söhngen will be the new CEO of
MOLOGEN AG
Berlin, July 23, 2015 - The Supervisory Board of biotechnology company
MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive
Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from
November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION
Deutschland GmbH. She will remain at PAION in her role as Chief Medical
Officer (CMO) up to October 31, 2015, with responsibility for phase I to IV
clinical development, regulatory and approval issues, pharmaceutical drug
safety, quality assurance, project management, Human Resources (HR),
Intellectual Property (IP) as well as preclinical research and development.
In addition, Dr. Söhngen played a decisive role in the company's successful
financing and licensing agreements.
When she assumes the role of CEO at MOLOGEN, she will be in charge of
Research, Business Development, Strategy and Partnering. Dr. Matthias
Schroff will resign from his post as chairman of the Executive Board on
October 31, 2015 and will be leaving the Executive Board with effect from
December 31, 2015, by mutual agreement with the Supervisory Board. In the
interim period from November 1, 2015 to December 31, 2015, Dr. Schroff
intends to provide support as an Executive Board Member, cooperating with
Dr. Söhngen to ensure a smooth transition of the chairmanship.
In addition, Jörg Petraß (Chief Financial Officer; CFO) also took the
decision in mutual agreement to not extend his contract, which is due to
expire on December 31, 2015, and will be leaving the Executive Board.
However, he has offered to act as a consultant for a transitional period to
enable orderly succession planning and the induction of his successor.
Oliver Krautscheid, Chairman of the Supervisory Board of MOLOGEN AG: "We
are delighted that Dr. Söhngen, an extremely competent biotech and pharma
manager, has agreed to take on the post of CEO. As co-founder of a
successful listed German company, she has already proved her credentials as
an entrepreneur in the biotech and pharma sector. She is a renowned biotech
and pharma expert, who has acquired a wealth of experience in clinical
research through to the approval of pharmaceutical products and has
negotiated several successful in- and out-licensing deals. This means she
is an ideal choice for the post of CEO, in order to lead MOLOGEN AG through
PRESS RELEASE N 11 / 2015 of 07/23/2015
Dr. med. Mariola Söhngen will be the new CEO of
MOLOGEN AG
Berlin, July 23, 2015 - The Supervisory Board of biotechnology company
MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive
Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from
November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION
Deutschland GmbH. She will remain at PAION in her role as Chief Medical
Officer (CMO) up to October 31, 2015, with responsibility for phase I to IV
clinical development, regulatory and approval issues, pharmaceutical drug
safety, quality assurance, project management, Human Resources (HR),
Intellectual Property (IP) as well as preclinical research and development.
In addition, Dr. Söhngen played a decisive role in the company's successful
financing and licensing agreements.
When she assumes the role of CEO at MOLOGEN, she will be in charge of
Research, Business Development, Strategy and Partnering. Dr. Matthias
Schroff will resign from his post as chairman of the Executive Board on
October 31, 2015 and will be leaving the Executive Board with effect from
December 31, 2015, by mutual agreement with the Supervisory Board. In the
interim period from November 1, 2015 to December 31, 2015, Dr. Schroff
intends to provide support as an Executive Board Member, cooperating with
Dr. Söhngen to ensure a smooth transition of the chairmanship.
In addition, Jörg Petraß (Chief Financial Officer; CFO) also took the
decision in mutual agreement to not extend his contract, which is due to
expire on December 31, 2015, and will be leaving the Executive Board.
However, he has offered to act as a consultant for a transitional period to
enable orderly succession planning and the induction of his successor.
Oliver Krautscheid, Chairman of the Supervisory Board of MOLOGEN AG: "We
are delighted that Dr. Söhngen, an extremely competent biotech and pharma
manager, has agreed to take on the post of CEO. As co-founder of a
successful listed German company, she has already proved her credentials as
an entrepreneur in the biotech and pharma sector. She is a renowned biotech
and pharma expert, who has acquired a wealth of experience in clinical
research through to the approval of pharmaceutical products and has
negotiated several successful in- and out-licensing deals. This means she
is an ideal choice for the post of CEO, in order to lead MOLOGEN AG through
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte